Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (82)

2024

  1. Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia

    Antioxidants, Vol. 13, Núm. 9

  2. Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche’s Endocannabinoid System Projects

    Chimia, Vol. 78, Núm. 7-8, pp. 499-512

  3. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

    Neuropharmacology, Vol. 237

  2. Endocannabinoid-Binding Receptors as Drug Targets

    Methods in molecular biology (Clifton, N.J.), Vol. 2576, pp. 67-94

  3. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

    Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108

  4. The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy

    Brain Sciences, Vol. 13, Núm. 9

2022

  1. New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

    Biomolecules, Vol. 12, Núm. 9

  2. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

    Neuropharmacology, Vol. 205

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

  2. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  3. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

  4. Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System

    RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47

  5. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis

    Brain Pathology, Vol. 31, Núm. 6

  6. Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments

    Frontiers in Molecular Neuroscience, Vol. 13

  7. Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease

    Molecules, Vol. 26, Núm. 11

  8. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

    Molecular and Cellular Neuroscience, Vol. 110

  9. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  10. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

2020

  1. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

    Neurobiology of Disease, Vol. 141